Media

BONESUPPORT – CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

BONESUPPORT – CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration